Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis

References

• Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian simvastatin survival study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med.333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study), a prospective randomized controlled trial. Lancet368, 1155–1163 (2006).
   PubMed Web of Science ®Google Scholar
• Teramoto T, Shimano H, Yokote K et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother.11(5), 817–828 (2010).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Yokote K, Saito Y. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin. Pharmacother.8, 2315–2327 (2007).
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Teramoto T et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis162(2), 373–379 (2002).
   PubMed Web of Science ®Google Scholar
• Teramoto T, Saito Y, Yamada N et al. Clinical safety and efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia. Results of a multicenter long-term study. J. Clin. Ther. Med.17(6), 885–914 (2001).
   Google Scholar
• Sone H, Takahashi A, Shimano H et al. HMG-CoA reductase inhibitor decreases small dense LDL and remnant-like particle cholesterol in patients with Type-2 diabetes. Life Sci.71(20), 2403–2412 (2002).
   PubMed Web of Science ®Google Scholar
• Noji Y, Higashikata T, Inazu A et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis163(1), 157–164 (2002).
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Saito Y, Ito H et al. Efficacy and safety of NK-104 (pitavastatin), a new HMG-CoA reductase inhibitor in the elderly patients with hyperlipidemia. Geriatr. Med.39, 849–860 (2001).
   Google Scholar
• Kurihara Y, Douzono T, Kawakita K et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet) – Livalo effectiveness and safety (LIVES) Study. Jpn Pharmacol. Ther.36, 709–731 (2008).
   Google Scholar
• Teramoto T, Shimano H, Yokote K et al. Effects of pitavastatin (Livalo tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia – sub-analysis of Livalo Effectiveness and Safety (LIVES) study. J. Atheroscler. Thromb.16, 654–661 (2009).
   PubMed Web of Science ®Google Scholar
• Kimura K, Shimano H, Yokote K et al. Effects of pitavastatin (Livalo tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease-sub-analysis of the Livalo Effectiveness and Safety (LIVES) study. J. Atheroscler. Thromb.17(6), 601–609 (2010).
   PubMed Web of Science ®Google Scholar
• Teramoto T, Sasaki J, Ueshima H et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J. Atheroscler. Thromb.14(2), 45–50 (2007).
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of low density cholesterol in plasma without the use of a centrifuge. Clin. Chem.18, 449–502 (1972).
   PubMed Web of Science ®Google Scholar
• Bianchi S, Bigazzi R, Caiazza A et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis.41, 565–570 (2003).
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol.17, 2006–2016 (2006).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J. Am. Soc. Nephrol.14, 1605–1613 (2003).
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J. Clin. Pathol.57, 728–734 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J. Am. Coll. Cardiol.51, 1448–1454 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis.53, 982–992 (2009).
   PubMed Web of Science ®Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on HDL-cholesterol levels and glucose metabolism in Japanese patients with elevated levels of LDL-cholesterol and glucose intolerance. Clin. Ther.30(6), 1089–1101 (2008).
   PubMed Web of Science ®Google Scholar
• Maejima T, Yamazaki H, Aoki T et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun.324, 835–839 (2004).
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med.139, 137–147 (2003).
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med.351, 1296–1305 (2004).
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet375, 2073–2081 (2010).
   PubMed Web of Science ®Google Scholar
• van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant.16, 2152–2157 (2001).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care28, 2728–2732 (2005).
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Watson KE, Fogelman AM et al. HDL function: recent advances. J. Am. Coll. Cardiol.46, 1792–1798 (2005).
   PubMed Web of Science ®Google Scholar
• Sasaki J, Iwashita M, Kono S et al. Statins: beneficial or adverse for glucose metabolism. J. Atheroscler. Thromb.13, 123–129 (2006).
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J et al. Statin therapy and risk of developing Type 2 diabetes: a meta-analysis. Diabetes Care32, 1924–1929 (2009).
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet375, 735–742 (2010).
   PubMed Web of Science ®Google Scholar
• Hiro T, Kimura T, Morimoto T et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). J. Am. Coll. Cardiol.54(4), 293–302 (2009).
   PubMed Web of Science ®Google Scholar